• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Inflamm Res . SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19

tetano

Editor, Senior Moderator
Inflamm Res


. 2026 Jun 20;75(1):143.
doi: 10.1007/s00011-026-02244-3.
SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19

Franklin Pereira Araújo[SUP] #[/SUP][SUP] 1 2 [/SUP], Geovane Marques-Ferreira[SUP] #[/SUP][SUP] 1 [/SUP], Camila Pacheco Silveira Martins da Mata[SUP] 1 3 [/SUP], Erik Vinicius de Sousa Reis[SUP] 1 [/SUP], Laura Cardoso Corrêa-Dias[SUP] 1 [/SUP], Ágata Lopes-Ribeiro[SUP] 1 [/SUP], Caio Wilker-Teixeira[SUP] 1 [/SUP], Gabriel Eduardo Ribeiro Mendes[SUP] 1 [/SUP], Vanessa Peruhype-Magalhães[SUP] 2 [/SUP], Ana Carolina Campi-Azevedo[SUP] 2 [/SUP], Olindo Assis Martins-Filho[SUP] 2 [/SUP], Andréa Teixeira-Carvalho[SUP] 4 [/SUP], Jordana Grazziela Alves Coelho-Dos-Reis[SUP] 5 [/SUP]


Affiliations
Abstract

Background: At the end of 2019, severe acute respiratory syndrome (SARS) caused by the novel coronavirus SARS-CoV-2 emerged in China, representing one of the most significant global health threats of the twenty-first century. This study aimed to evaluate the phenotypic and cellular activation of epithelial cells in tracheal aspirate samples from patients with severe COVID-19.
Methods: A total of 48 samples were collected from 28 mechanically ventilated patients and analyzed using flow cytometry and conventional microscopy.
Results: The results revealed a high prevalence of basal, ciliary, undifferentiated cells, and pneumocytes displaying morphological abnormalities. Samples were classified into hypocellular and hypercellular profiles based on total cell counts. These profiles were associated with clinical outcomes, with hypercellular samples more frequently observed in patients who died. Hypercellular samples exhibited increased frequencies of basal, undifferentiated cells and pneumocytes, as well as a greater presence of CD45⁺ cells with elevated HLA-DR expression, indicating an influx of activated leukocytes and antigen-presenting cells. In contrast, hypocellular samples showed a higher proportion of CD45⁻PanCK⁺ cells, reflecting a predominance of epithelial cells. Hypercellular samples also demonstrated increased EpCAM⁺PanCK⁺ epithelial cells with more expression of Spike in the context of intense inflammation. ICAM-1 expression was elevated in CD45⁺ cells from hypercellular samples, while reduced in CD45⁻ cells. Finally, a superior connectivity was found for networks of correlations of hypercellular samples, especially amongst the compartments of cells expressing EpCAM.
Conclusion: Together, these findings identify two distinct cellular profiles that may serve as prognostic indicators in severe COVID-19.

Keywords: Cytokeratin; EpCAM; Epithelial cells; ICAM-1; Severe COVID-19.

 
Back
Top